Hindustan Bio Sciences Ltd
Incorporated in 2000, Hindustan Biosciences Ltd manufactures & sells pharmaceutical products.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Information Technology Information Technology IT - Software Software Products
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Foreign Exchange Earnings INR Lakhs ・Standalone data |
|
||||||||||
| Revenue from Operations INR Lakhs ・Standalone data |
|||||||||||
| Number of Employees Absolute ・Standalone data |
|||||||||||
| Relative Quantity Performance (Erythropoietin) Percentage of Previous Year ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2 Jun - Newspaper publication as per regulation 47 of SEBI (LODR) 2015.
-
Appointment Of Internal Auditor For The Year 2026-27
30 May - Board approved audited FY2026 standalone results and reappointed Mr. GBK Viswanadham as internal auditor for FY2026-27.
- Audited Financial Results For The Fourth Quarter And Financial Year Ended 31St March 2026 30 May
-
Board Meeting Outcome for Approved Audited Results For The Fourth Quarter And Financial Year Ended 2026
30 May - Board approved audited FY26 standalone results and appointed GBK Viswanadham as internal auditor for FY27.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
21 May - Hindustan Bio Sciences filed FY2025-26 annual secretarial compliance report; no non-compliances noted.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
HBSL previously sourced bulk drugs (APIs) and drug intermediates and holds an import license from GEAC for Recombinant Human Erythropoietin, following clinical trials. It now manufactures and markets a wide range of premium finished dosage forms in pharmaceutical and biotechnology segments.